

Countable Labs.

ANCORA HEME ONCOLOGY ASSAYS

Heme oncology clinical research asks more of every sample.

Direct molecular counting for fusion,
mutation, and resistance research.



THE CHALLENGE

One sample. Many questions.

- Hematologic malignancy research spans fusions, isoforms, mutations, and resistance markers.
- Most labs juggle separate assays, standards, and reporting for each.
- A limited sample may need to cover baseline, MRD monitoring, and resistance studies.

HEME ONCOLOGY ASSAYS

Meet the Ancora Assay family.

Ancora brings direct molecular counting to a growing portfolio of heme oncology assays on the Countable PCR platform. The assay portfolio supports baseline characterization, longitudinal measurement, and resistance investigation through a shared platform and reporting environment.

<1% CV
across runs

Zero dead
volume

Results in as
little as 3 hours

Built for:

Molecular Pathology Labs ■ Academic Translational Centers ■ Clinical Research Organizations ■
Acute Myeloid Leukemia (AML) Drug Developers ■ Chronic Myeloid Leukemia (CML) Drug Developers




In our benchmarking work, the biggest difference we saw with Countable PCR was the precision. We measured coefficients of variation, which were substantially tighter than what we see with conventional FDA-approved RT-PCR. When you're tracking a patient's molecular response over time, that kind of reproducibility matters."

Pamela Ward, PhD
Associate Professor Clinical Pathology
University of Southern California



Three research priorities across the Ancora portfolio.




Trust every result

Direct molecular counting

Measure target abundance from counted molecules rather than amplification-curve inference, with target-specific identification and automated reporting.

For longitudinal studies, this provides quantitative measurements researchers can follow across samples as the abundance of a fusion transcript or mutation changes.




Get more biological information from every sample

High-color multiplexing

Distinguish between multiple transcripts, isoforms, or mutations alongside reference targets within a single assay, capturing more data from each sample.

Researchers can examine which covered targets are present and measure their individual abundance, addressing multiple molecular questions without dividing limited material among separate single-target assays.



Expand capability without expanding workflow complexity

One platform, growing assay menu


Add new heme oncology research applications through the same Countable PCR workflow, imaging platform, and reporting environment.

Teams can select assays for baseline characterization, longitudinal tracking, or resistance investigation while retaining a familiar approach to running experiments and reviewing results.

Every single molecule is now Countable.


Detect even the rarest signals with ultra-sensitive, single-molecule precision.

Every nucleic acid and molecule is physically separated into its own compartment and amplified without interference. By eliminating the bias and signal noise of traditional PCR, Countable PCR is ideally suited for applications that demand high accuracy and sensitivity, including oncology and laboratory-developed testing.




Eliminate PCR bias and simplify multiplexing with single molecule isolation across 30 million picoliter-sized compartments.

From baseline to resistance.




01 Characterize

Identify the fusion, isoform, or mutation.




02 Quantify

Count absolute target copies.



03 Track

Monitor target counts across longitudinal samples.



04 Investigate

Reflex to TKI resistance mutation testing.

Isoform(s) detected	Sample name	Sample ID	Sample quality*	%IS	MR	BCR::ABL 1 counts per 50 μ L	ABL 1 counts per 50 μ L
p210 (e14a2)	e14a2_lev el1_rep1	2I4989_01	Pass	17.023%	0.77	98,144	576,542
p210 (e14a2)	e14a2_lev el1_rep2	2I4989_02	Pass	17.263%	0.76	100,995	585,022
p210 (e14a2)	e14a2_lev el1_rep3	2I4989_03	Pass	16.941%	0.77	101,855	601,230
p210 (e14a2)	e14a2_lev el1_rep4	2I4989_04	Pass	17.138%	0.77	103,589	604,441

BCR::ABL1 assay report results summary (%IS), generated by Countable Control Software. Includes p210 isoforms (e13a2, e14a2) only.

From counted molecules to results.

Countable Control Software identifies and counts each assay target, provides automated QC metrics for the run, and generates an assay-specific report. Labs can review target counts and results without the need for complex bioinformatics pipelines.

Explore the Ancora assay family.

BCR::ABL1

Quantify four *BCR::ABL1* transcripts plus *ABL1* beyond MR5.0 (at $\geq 1M$ *ABL1* copies)

Targets *e14a2*, *e13a2*, *e1a2*, *e19a2* + *ABL1*

KMT2A-r

Detect *KMT2A* rearrangements for MRD tracking

Covers 18 fusion transcripts across six partners

***ABL1* TKI Resistance Mutation Phasing**

Perform TKI resistance testing following a positive *BCR::ABL1* result

T315I, E255K, E255V + WT + *ABL1*

***KIT* D816V**

Detect *KIT* D816V down to 0.015% VAF alongside *KIT* WT

Targets D816V + *KIT* WT

PML::RARA

Count all three canonical *PML::RARA* isoforms plus *ABL1*

Targets *bcr1*, *bcr2*, *bcr3* + *ABL1*

***NPM1* Mutation**

Quantify *NPM1* Type A, B, and D mutations directly from RNA

Covers Types A, B, and D + *ABL1*

See the full assay list at countablelabs.com/heme-oncology.



Fulfilling exhaustive RT-PCR requests for *KMT2A* and other leukemia fusions is often hindered by limited sample volumes. Countable PCR overcomes this barrier through highly multiplexed, high-throughput assays. By seamlessly handling both low-volume inputs for initial multi-target screening and high-volume inputs for precise disease monitoring of a specific target, it offers an exceptionally versatile diagnostic platform for us and our needs.”

Dongbin Xu, PhD


Vice President, Laboratory Director
HematoLogics, Inc.

THREE WAYS TO ACCESS ANCORA




Kits

Choose a kit and run Ancora in your lab.



Services

Send samples to Countable assay services and run a study.



Custom

Build a custom assay around your targets.

The Ancora assay portfolio
will continue to grow.

Visit **countablelabs.com/heme-oncology**
for the latest assay availability and details.

Countable Labs.

For Research Use Only.
Not for Use in Diagnostic Procedures.

© 2026 Countable Labs, Inc.

October 2026 MK063 Rev1.0